TABLE 2.

Burkholderia pseudomallei in cystic fibrosis patients reported in the literature

Reference	Age (yr), sex	Origin	Clinical presentation	Treatmenta	Outcome and follow-up
4	20, male	Malaysia	NDb	ND	ND
17	38, male	Thailand	Multiple lung infections	i.v. CAZ, PIP, and TZP with or without aminoglycosides or CIP for 2 wk	Multiple exacerbations, at least 7 yr of documented colonization
18	25, female	Thailand	Acute lung infection	Continuous i.v. CAZ + SXT for 6 wk + oral SXT, DOX, and CHL for 30 wk	Clinical recovery, eradication of B. pseudomallei, 1 yr of follow-up
6	9, male	Australia	Acute lung infection and bacteremia	i.v. CAZ + TOB, CAZ + MEM, SXT, and MEM; duration of treatment ND	Clinical recovery after prolonged therapy, development of resistance to multiple drugs
6	7.5, female	Australiac	ND	Oral DOX	Clinically healthy, B. pseudomallei in sputum for a time, follow-up ND
6	10, male	Australia	Colonization, mild infection	i.v. CAZ + SXT for 2 wk + SXT for 3 mo	Healthy, eradication of B. pseudomallei, 18 mo of follow-up
6	38, male	Australia	Acute lung infection	i.v. CAZ + TOB, duration ND	B. pseudomallei recovered 3 mo after completion of therapy
14	23, male	Australia	Pulmonary exacerbations; severe respiratory infection	Oral SXT + AMC; i.v. CAZ + MEM + oral SXT with or without oral TET and CIP for 8 wk	Death, persistent recovery of B. pseudomallei from sputum, follow-up ND
12	36, male	Australia	Frequent pulmonary exacerbations	i.v. CAZ, MEM, and oral SXT either alone or in combination; oral TET or SXT between exacerbations	Progressive deterioration, persistent recovery of B. pseudomallei from sputum, follow-up ND
14	15, male	Australia	Asymptomatic	None	Follow-up ND
14	24, female	Australiac	Two severe exacerbations	i.v. CAZ + MEM + TOB for 3 wk	Clinically successful treatments, microbiologic outcome ND
1	17, male	Malaysia	Chronic worsening respiratory symptoms and deteriorating lung function	i.v. SXT + CAZ for 2 mo followed by oral DOX + SXT for 4 mo	Lung function recovery, negative sputum cultures, 5 mo of follow-up

^ai.v., intravenous; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; DOX, doxycycline; MEM, meropenem.

^bND, not described.

^cSubtropical region.